Business Wire

Parlem Selects MDS Global for Business-Optimising Analytics Solution

Jaa

MDS Global Ltd, a leading BSS-as-a-Service provider today announced next generation service provider Parlem as a new customer. Parlem has chosen MDS Global’s VNOnDemand Analytics as a packaged service, in order to help answer critical business questions and deliver valuable benefits.

Parlem, an MVNO based in Barcelona, Catalonia, offers communication services including mobile, fixed, cloud applications and ADSL/FTTH services to enterprises. Services can be managed via apps as part of a user-friendly service providing control over elements such as virtual lines, visual voicemail and VoIP. The digital nature of the offer provides an opportunity for consumer behaviour to be analysed to ensure that Parlem continues to closely understand their subscribers needs.

MDS Global’s VNOnDemand Analytics solution further facilitates Parlem’s customer-centricity. Providing insight on service usage, profitability, sales, customer segmentation and business assurance, the cloud service offers the following benefits:

  • Prioritisation and optimisation of services based on popularity/revenue.
  • Visibility of targets and costs during the planning process.
  • Optimisation of sales channels.
  • An understanding of where to target retention programs.
  • Visibility of business process performance.

All of these benefits will ultimately lead to improved customer service, greater customer retention, and an improved product offering, tailored to their market.

Parlem’s founder and CEO, Ernest Pérez-Mas says, “Ensuring that we offer a personalised service to our customers is an essential part of our appeal in the market. Every customer is unique and MDS Global’s analytics solution will provide us with greater visibility of what we’re doing right, and wrong, in order to sustain an existing subscriber base and to expand it.”

He continues, “Utilising analytics as a service enables us to free up vital internal resources with the reassurance that we can access performance data that is being analysed hour by hour.”

MDS Global, CEO, Gary Bunney said, “Parlem can continue to excel in resource and service management, based on solid business intelligence fed to them by our analytics solution. It will help the company achieve greater control and profitability in its business. We are proud to help Parlem drive its next phase of growth and market dominance.”

About MDS Global

MDS Global is a leading BSS-as-a-Service provider of VNO, B2B and IoT solutions. We look after all aspects of monetisation, assurance and customer steering for complex products and services. We offer a digital operating model in a DevOps context, which enhances stakeholder experiences and provides unprecedented business agility.

Headquartered in the UK, MDS Global’s customers include BT Business (UK), eir (Ireland), iD Mobile from Dixons Carphone (UK), TalkTalk (UK), Telefónica (UK), Vodafone (Germany, Greece and Belgium), Orange (Belgium), KPN (Netherlands) and Telia (Denmark).

For more information, please visit www.mdsglobal.com.

Contact information

Martine Naughton
MDS Global
Email: martine.naughton@mdsglobal.com
Tel: +44 (0) 7909 475815

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Vertex Announces European Commission Approval for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease21.1.2019 12:00Tiedote

Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label extension for ORKAMBI® (lumacaftor/ivacaftor) for the treatment of children with cystic fibrosis (CF) aged 2 to 5 years old who have two copies of the F508del mutation, the most common form of the disease. “Today’s approval by the European Commission brings us one step closer to our goal of bringing treatment to all people living with CF,” said Reshma Kewalramani, MD, Executive Vice President, Global Medicines Development and Medical Affairs and Chief Medical Officer at Vertex. ‘‘By treating the underlying cause of disease early, we can potentially modify its course and offer patients the chance of improved outcomes.’’ The label update is based on data from a Phase 3 open-label safety study in 60 patients that showed treatment with lumacaftor/ivacaftor was generally well tolerated for 24 weeks, with a safety profile in these pediatric patients generally consistent with

Anticipation Builds as MWC19 Barcelona Approaches21.1.2019 12:00Tiedote

The GSMA today announced final updates for MWC19 Barcelona (formerly Mobile World Congress), including additional keynote speakers, participating companies, programmes and events. Taking place 25-28 February 2019, with events being staged at Fira Gran Via, Fira Montjuïc and La Farga L’Hospitalet, MWC19 Barcelona is set to attract more than 107,000 professionals from over 200 countries and territories. “With the anticipated arrival of 5G, this year’s event is set to be one of the most exciting as the industry convenes to showcase Intelligent Connectivity across new technologies on the brink of reaching millions of people across the world,” said John Hoffman, CEO, GSMA Ltd. “Over the four days of MWC19, attendees will have the opportunity to hear from leaders who are driving innovation and we look forward once again to welcoming the mobile world to Barcelona.” Global Leaders to Keynote The GSMA announced the addition of several new keynote speakers for MWC19 including executives from lea

B2C2 Launches Streaming OTC Pricing with Point-and-Click Execution21.1.2019 12:00Tiedote

B2C2, one of the largest cryptocurrency liquidity providers and the leader in electronic OTC trading, today announced the launch of streaming pricing with point-and-click execution on its OTC platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190121005063/en/ Max Boonen, Founder and CEO of B2C2 (Photo: Business Wire) For the first time, B2C2’s clients will be able to view and execute trades on a real-time two-way market, via the firm’s secure web interface. The new functionality allows market participants to easily monitor live pricing in user-defined quantities and execute with the click of a button, as they would on traditional FX trading platforms. The launch rounds out a number of milestones for B2C2 in 2018, including surpassing 2017 peak volumes; rolling out a completely redesigned front-end; forming integration partnerships with the major liquidity hubs; and launching a research offering. Founded in 2015, B2C2 i

Alnylam Pharmaceuticals and Medison Pharma Partner to Commercialize RNAi Therapeutics in Israel21.1.2019 11:00Tiedote

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma, Israel’s leading commercial partner for innovative pharmaceuticals, announced today an exclusive agreement to commercialize ONPATTRO®, the first-ever commercialized RNAi therapeutic, as well as other investigational therapeutics under development in the Alnylam RNAi portfolio. “Our partnership with Medison marks an important step in our global commercial expansion and signals our intent to ensure that patients suffering from serious rare diseases have access to our medicines, regardless of location,” said Theresa Heggie, SVP and Head of Europe, Middle East and Africa, and Canada, Alnylam Pharmaceuticals. “Medison has a strong organization with a proven track record of commercializing orphan products successfully, together with an infrastructure uniquely suited to supporting patients suffering from rare diseases in Israel and providing access to our potentially transformational thera

Gore Introduces GORE® TAG® Conformable Thoracic Stent Graft with Reduced Profiles in Europe21.1.2019 11:00Tiedote

W. L. Gore & Associates, Inc. (Gore) today introduced reduced profiles for the most commonly used diameters of the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System. The reduced profile allows physicians to perform TEVAR in patients with smaller vessels where access is challenging and aortic anatomy is tortuous, expanding the availability of Gore’s thoracic stent graft to a greater population of patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190121005042/en/ GORE(R) TAG(R) Conformable Thoracic Stent Graft with ACTIVE CONTROL System (Photo: Business Wire) The GORE® TAG® Conformable Thoracic Stent Graft was modified to reduce the delivery profile of the 31, 37, and 40 mm device diameters by 2 Fr for all lengths. The reduction in profile, through the use of a smaller diameter primary sleeve, is the only change to the device. The stent graft leverages the same predictable outcomes of the time-teste

HCL 2030 Ecosystem Platform to Explore Societal Implications of Emerging Technology at the World Economic Forum21.1.2019 10:26Tiedote

HCL Technologies (HCL), a leading global technology company and the World Economic Forum’s Strategic Partner, today announced its largest presence to date at the side-lines of World Economic Forum’s Annual Meeting in Davos scheduled from 21st January 2019 to 25th January 2019. The company will host a three-day event in a special Pavilion that will feature a technology showcase, thought-leadership programs, as well as a number of high-level networking and social events throughout the tenure of the conference. The overarching theme of the HCL and Fast Company programs will explore how humanity’s relationship with technology will evolve through the next decade of rapid innovation. HCL has partnered with Fast Company to develop a thought-leadership track that includes three panel discussion breakfasts. As part of the theme of Human-Machine Harmony, HCL is launching the HCL 2030 Platform, together with its ecosystem of partners and stakeholders, that will conduct in-depth explorations and d

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme